Aclarion (ACON) investor relations material

Executive summary

• Revenue for Q2 2026 increased 30.5% year-over-year to $25,208, driven by higher Nociscan report sales in the UK following new local coverage decisions.

• Net loss widened to $2.75 million for Q2 2026 from $1.60 million in Q2 2025, reflecting higher operating expenses across all categories.

• Operating expenses surged due to expanded sales force, increased clinical trial activity, and higher legal, investor relations, and franchise tax costs.

Financial highlights

• Six-month revenue rose 21% year-over-year to $46,348, while cost of revenue decreased 8.9% to $34,301, improving gross margin.

• Operating expenses for the first half of 2026 totaled $5.9 million, up from $3.2 million in the prior year period.

• Net loss for the first half of 2026 was $5.60 million, compared to $3.64 million in the same period of 2025.

• Interest income increased to $290,381 for the first half of 2026, reflecting higher cash balances.

Outlook and guidance

• Management expects continued revenue growth as more insurance payors are added and scan volumes increase.

• Operating expenses, particularly in sales, marketing, and R&D, are expected to remain elevated as commercialization and product development efforts expand.

• Current cash resources are projected to fund operations into the second half of 2027.